Northland Capital Markets Remains Bullish on Flexion Therapeutics (FLXN) After Being Granted Fast Track Status by FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pre-Open Stock Movers 09/02: (SURG) (VRA) (WMGI) Higher; (RJET) (DGLY) (HTWR) Lower (more...)
September 2, 2015 9:23 AM EDTA listing of stocks moving in the pre market trading session:
Synergetics USA, Inc. (NASDAQ: SURG) 53% HIGHER; Synergetics USA and Valeant Pharmaceuticals International ("Valeant"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), announced that they have entered into a definitive agreement under which Valeant will acquire Synergetics for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional cash payments... More
After-Hours Stock Movers 09/01: (HRB) (FLXN) (GTN) Higher; (AVAV) (SCVL) (AMBA) Lower (more...)
September 1, 2015 5:15 PM EDTAeroVironment (NASDAQ: AVAV) 7.6% LOWER; reported Q1 EPS of ($0.30), $0.15 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $47.1 million versus the consensus estimate of $53.92 million. As of August 1, 2015, funded backlog (unfilled firm orders for which funding is currently appropriated to us under a customer contract) was $89.0 million compared to $64.7 million as of April 30, 2015.
H&R Block (NYSE: HRB) 7.4% HIGHER; announced that it has successfully closed its transaction to divest H&R Block... More
Flexion Therapeutics' (FLXN) FX006 Granted FDA Fast-Track Designation
September 1, 2015 4:03 PM EDTFlexion Therapeutics (NASDAQ: FLXN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for FX006, Flexion's late-stage, lead drug candidate that is designed as a treatment for the more than four million U.S. patients receiving intra-articular (IA) injections for osteoarthritis (OA) of the knee. Flexion is currently studying FX006 in a Phase 2b... More
Flexion Therapeutics' (FLXN) FX006 Granted Fast Track Status
September 1, 2015 4:02 PM EDTFlexion Therapeutics, Inc. (Nasdaq: FLXN) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for FX006, Flexion's late-stage, lead drug candidate that is designed as a treatment for the more than four million U.S. patients receiving intra-articular (IA) injections for osteoarthritis (OA) of the knee. Flexion is currently studying FX006 in a Phase 2b pivotal trial, with top-line data expected to be announced soon, as well as in a Phase 3 clinical trial for which it expects to share data in the first quarter of... More
